{"id":"tqb2450-anlotinib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TQB2450 targets multiple tyrosine kinases, including VEGFR, PDGFR, and c-Kit, while Anlotinib specifically inhibits VEGFR. This dual inhibition is thought to suppress tumor growth and angiogenesis.","oneSentence":"TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:36.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT04574284","phase":"PHASE2","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-09-29","conditions":"Advanced Endometrial Cancer","enrollment":170},{"nctId":"NCT06939452","phase":"PHASE2","title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","status":"RECRUITING","sponsor":"Yongxu Jia","startDate":"2023-06-07","conditions":"Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","enrollment":37},{"nctId":"NCT06699498","phase":"PHASE2","title":"Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-03","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1","enrollment":45},{"nctId":"NCT04523272","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-25","conditions":"Advanced Renal Cancer","enrollment":528},{"nctId":"NCT06141226","phase":"PHASE2","title":"Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-12","conditions":"Non-small-cell Lung Cancer","enrollment":148},{"nctId":"NCT04891900","phase":"NA","title":"TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-05-10","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":25},{"nctId":"NCT06469879","phase":"PHASE3","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-09","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":358},{"nctId":"NCT06475599","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":"Endometrial Cancer","enrollment":420},{"nctId":"NCT06475287","phase":"PHASE2","title":"HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-20","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06222944","phase":"PHASE2","title":"Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2024-02-25","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":90},{"nctId":"NCT05812430","phase":"PHASE2","title":"Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-04-10","conditions":"Advanced Biliary Tract Cancer","enrollment":20},{"nctId":"NCT06031480","phase":"PHASE2","title":"Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT05942508","phase":"PHASE1","title":"A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2023-05-30","conditions":"Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy","enrollment":20},{"nctId":"NCT05913089","phase":"PHASE2","title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06-14","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT05038813","phase":"PHASE2","title":"Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-03-14","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05252078","phase":"PHASE2","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-06-02","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases","enrollment":30},{"nctId":"NCT05608785","phase":"PHASE1, PHASE2","title":"Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-01-01","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":45},{"nctId":"NCT05111366","phase":"PHASE2","title":"TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Xianhai Mao","startDate":"2022-01-06","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":37},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT05311319","phase":"PHASE2","title":"HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-01-11","conditions":"Hepatocarcinoma","enrollment":70},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT05145218","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-09-28","conditions":"Recurrent Platinum-resistant Ovarian Cancer","enrollment":405},{"nctId":"NCT04964479","phase":"PHASE3","title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-08-06","conditions":"Non Small Cell Lung Cancer","enrollment":375},{"nctId":"NCT05013697","phase":"PHASE2","title":"TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2021-09","conditions":"Esophageal Neoplasms","enrollment":48},{"nctId":"NCT04888546","phase":"PHASE1, PHASE2","title":"TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-30","conditions":"Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi","enrollment":20},{"nctId":"NCT04809142","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-02-04","conditions":"Advanced Biliary Cancer","enrollment":392},{"nctId":"NCT04665609","phase":"PHASE3","title":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03-05","conditions":"Hepatocellular Carcinoma, Thermal Ablation, Anlotinib","enrollment":80},{"nctId":"NCT04236362","phase":"PHASE1, PHASE2","title":"A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-02-27","conditions":"Gynecological Cancer","enrollment":90},{"nctId":"NCT04611711","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors","status":"UNKNOWN","sponsor":"Peking University","startDate":"2020-11-01","conditions":"Patients With Digestive System Tumors Resistant to PD-1 Inhibitors","enrollment":60},{"nctId":"NCT04405505","phase":"PHASE3","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-06-01","conditions":"Triple Negative Breast Cancer","enrollment":332},{"nctId":"NCT04234607","phase":"PHASE3","title":"A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":738},{"nctId":"NCT03825705","phase":"PHASE1, PHASE2","title":"A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-04-23","conditions":"Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT03991975","phase":"PHASE1, PHASE2","title":"Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-11","conditions":"Advanced Acral Malignant Melanoma","enrollment":42},{"nctId":"NCT03996408","phase":"PHASE1, PHASE2","title":"Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-24","conditions":"Advanced Cholangiocarcinoma","enrollment":42},{"nctId":"NCT03897283","phase":"PHASE1","title":"Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-20","conditions":"Advanced Solid Tumors","enrollment":22},{"nctId":"NCT03855358","phase":"PHASE1","title":"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-05-09","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT03910127","phase":"PHASE1","title":"Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-11","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT03983928","phase":"PHASE1, PHASE2","title":"Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-06-03","conditions":"Lung Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQB2450+Anlotinib","genericName":"TQB2450+Anlotinib","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor. Used for Non-small cell lung cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}